

Curriculum Vitae

Gregory Yoke Hong LIP, MD, FESC

Application for the position of Nominating Committee, representing the ESC Associations, Councils and Working Groups

Personal Information:

Place and Date of Birth: Ipoh, Malaysia: 6 June 1964

Nationality: British

Current Position and Professional Address

Price-Evans Chair of Cardiovascular Medicine, University of Liverpool, UK (from 1 Feb 2022)
Liverpool Centre for Cardiovascular Science at the University of Liverpool, Liverpool.
and Liverpool Heart & Chest NHS Foundation Trust. **Address: William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, United Kingdom**



Education and Postgraduate Training

UNIVERSITY EDUCATION: University of Glasgow, Glasgow G12 8QQ.

Graduated July 1988 with the degrees of M.B., Ch.B. (with commendation) and most distinguished graduate in medicine and surgery of the year: BRUNTON MEMORIAL PRIZE and Robert Fullerton Prize.

MEMBERSHIP OF THE ROYAL COLLEGES OF PHYSICIANS. M.R.C.P.(U.K.) March 1991

DIPLOMA OF FORENSIC MEDICINE (DFM) with Class Prize. September 1993

DOCTOR OF MEDICINE (M.D.) University of Glasgow, September 1994

European Society of Cardiology Activities

- **2020-2026 ESC Council on Stroke** (2020-22; Council secretary, administration/research oversight; Scientific Documents chair, responsible for position papers; 2022-24, Chairman-Elect; **2024-2026 Chairperson**); Chaired position paper from the Council on “Integrated care for optimizing the management of stroke and associated heart disease” with multidisciplinary writing group (PMID: 35552401). Introduced new workstreams on scientific initiatives (systematic reviews, global surveys on stroke-heart topics, cost effectiveness analyses, core outcome sets), scientific documents, and education initiatives (blogs, podcasts) and basic/translational science. Programme chair for the 2025 ESC Heart & Stroke Eurothrombosis joint meeting in Milan, and for 2026, in Prague.
- Committee member of the **ESC Clinical Practice Guidelines Committee (2024-2026)** [oversight of ESC guidelines and consensus papers] and **ESC Congress Programme Committee (2024-2026)**
- **ESC Working Group on Thrombosis** (Nucleus member 2020-present) Co-Chaired new consensus guidelines on bleeding risk assessment in atrial fibrillation (AF) and venous thromboembolism, 2022: PMID: 35323922); Writing group on WG Thrombosis paper on Acute, periprocedural and long-term antithrombotic therapy in older adults (PMID: 36477865).
- 2022-2024 Nucleus Member, **ESC Cardiovascular Roundtable**; think-tank for the ESC which links academia and industry, highlighting innovations, planning workshops and position papers.
- Chairman (2011-2015; and Executive Steering Committee, as ‘Past Chairman’ 2016-) of the **ESC EuroObservational Research Programme on Atrial Fibrillation (EORP-AF)**, defining the epidemiology and management of AF in Europe.
- Since 2016, I have chaired or contributed to multiple **ESC/European Heart Rhythm Association (EHRA)/Acute Cardiovascular Care Association (ACCA) consensus guidelines** eg. Arrhythmias in AF with Heart failure (2015, 2020); AF with Acute coronary syndrome/Stenting (2014); valvular AF, hypertension (2016-2017); real world observational studies in arrhythmia research (2020); risk assessment in cardiac arrhythmias (2020); Member, **ESC Clinical Practice Guideline Committee** (2014-2016; 2024-26). Peer reviewer of ESC/EHRA guidelines since 2012. Review Coordinator, 2015 ESC ventricular arrhythmia guidelines.

European Heart Rhythm Association (EHRA): EHRA Board member: Chair, Scientific Documents Committee (2015-2017), coordinated new guideline development/reviews & facilitated implementation/education. From 2017-2018, EHRA Governing Board as ‘Research Pillar’ Chair, responsible for scientific initiatives/innovation and scientific documents. **2022-2024 Chair of International Affairs Committee**, linking with international partner societies (Asia-

Pacific Heart Rhythm Society, Heart Rhythm Society, Latin America Heart Rhythm Society). I represent EHRA at the **Heart Rhythm Society Global Relations Committee** (2023-) linking arrhythmia practice groups internationally, and responsible for the webinar programme. Appointed as 'Global EP Leader' by the **Heart Rhythm Society** (2023).

Participation in Other International Scientific Committees

- Appointed as **Chairman of the Writing Group of the international American College of Chest Physicians (ACCP Guidelines on Antithrombotic therapy for AF** (10th edition, 2016-). Previously served as writing committee member for the 8th and 9th ACCP guideline editions. For the 9th ACCP guideline (2012), I was appointed as 'content expert' (ie. 'deputy editor') for the AF guideline chapter. Writing Committee for **ACCP COVID-19 arterial thrombosis guidelines** [2023].
- Committee member of the **American College of Cardiology** Scientific Publications Committee (2024-), providing general oversight of the ACC publications and journals.
- **International Academic Scientific Advisory Boards:** (i) Member of the Scientific Advisory Board (SAB) of Siriraj Center of Research Excellence – Cardiovascular disease (SiCORE-CVD), Faculty of Medicine Siriraj Hospital, **Mahidol University, Bangkok Thailand**; 2020-23 (ii) Member, Joint Scientific Advisory Board (SAB) of the Cardiovascular Diseases Translational Research Program (CVD TRP) and Cardiovascular Research Institute (CVRI), School of Medicine (NUSMed) at **National University of Singapore (NUS)** 2022-25.
- Expert medical advisory committee of 2 major international patient organisations involved in AF – **AF Association** (<http://www.atrialfibrillation.org.uk>) and **Stopafib.org** (<http://stopafib.org>) (both 2009, ongoing).

Editorial Boards

Editor in Chief (Clinical Studies) [2010-] of 'Thrombosis & Haemostasis'. Also regular Guest Editor for 'Circulation' (2009-), European Heart Journal-Cardiovascular Pharmacology, and American Heart Journal. I am a Deputy Editor (since 2023) for 'Europace' (the main journal for the European Heart Rhythm Association; Editorial Board since 2009-). Also, Associate Editor for JACC Asia (2023-). I am on the editorial boards of many of the main journals in the field, including the following: European Heart Journal, Circulation, Heart, American Journal of Cardiology, American Heart Journal, American Journal of Medicine, etc.

Leadership and Management Experience

Currently Director of the Liverpool Centre for Cardiovascular Science (LCCS), a multi-stakeholder research centre of excellence for the University of Liverpool, Liverpool John Moores University, Liverpool Heart & Chest NHS Foundation Trust (and other NHS partners) and Liverpool Health Partners: <https://www.liverpool.ac.uk/liverpool-centre-for-cardiovascular-science/> Chair or steering committee member of various clinical trials (eg. ENSURE-AF trial of cardioversion of AF) or global registries in cardiovascular disease (eg. GLORIA-AF).

Fellowships and Honours

FELLOW OF THE AMERICAN COLLEGE OF CARDIOLOGY (F.A.C.C.) August 1996

FELLOW OF THE EUROPEAN SOCIETY OF CARDIOLOGY (F.E.S.C.) June 1997

FELLOW OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH (F.R.C.P.Edin) Sept 1998

FELLOW OF THE ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF GLASGOW (F.R.C.P.Glasg) 1999

FELLOW OF THE ROYAL COLLEGE OF PHYSICIANS OF LONDON (F.R.C.P.Lond) May 2001

FELLOW OF THE EUROPEAN HEART RHYTHM ASSOCIATION (F.E.H.R.A.) December 2016

Associate Fellow, Higher Education Authority (AFHEA) March 2021 (PR210091)

International FELLOW OF THE ASIA-PACIFIC HEART RHYTHM SOCIETY (iFAPHRs) September 2023

Honorary FELLOW OF THE TAIWAN HEART RHYTHM SOCIETY (FTHRS) March 2024

Honorary FELLOW OF THE KOREAN HEART RHYTHM SOCIETY (FKHRS); June 2025

Honorary doctorates

DOCTOR MEDICINAE HONORIS CAUSA Aalborg University, Denmark: April 2013

DOCTOR HONORIS CAUSA, University of Medicine & Pharmacy "Carol Davila", Bucharest, Romania; Sept 2016

DOCTOR HONORIS CAUSA, Belgrade University, Republic of Serbia; October 2016

DOCTOR HONORIS CAUSA, Université de Tours, France, conferred March 2017

DOCTOR HONORIS CAUSA, Medical University of Silesia in Katowice, conferred July 2020

DOTTORE DI RICERCA (Dott. Ric. or Ph.D) HONORIS CAUSA in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy; conferred 2022

Honorary Fellowship (the university's highest honour) of Liverpool John Moores University; conferred October 2024 <https://www.ljmu.ac.uk/about-us/fellows/honorary-fellows-2024>

Honorary Memberships

Honorary Member of the Polish Cardiac Society, Hungarian Cardiac Society, Romanian Cardiac Society.

Top 10 Most Relevant Publications

	Reason for significance
1. Lip GY , Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest . 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584. Epub 2009 Sep 17	Original description of the CHA ₂ DS ₂ -VASc score; cited >8336 times (Google Scholar 30 March 2025)
2. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest . 2010 Nov;138(5):1093-100	Original description of HAS-BLED score; cited >5741 times (Google Scholar 30 March 2025)
3. Apostolakis S, Sullivan RM, Olshansky B, Lip GY . Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAME-TT ₂ R ₂ score. Chest 2013; 144: 1555-1563	Original description of SAME-TT ₂ R ₂ score, cited >699 times (Google Scholar 30 March 2025)
4. Lip GYH . The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol . 2017 Nov;14(11):627-628. doi: 10.1038/nrcardio.2017.153.	Original description of Atrial fibrillation Better Care (ABC) Pathway for integrated care of atrial fibrillation, cited >634 times (Google Scholar 30 March 2025)
5. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Bartels DB, Lip GY ; GLORIA-AF Investigators. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. J Am Coll Cardiol . 2017 Feb 21;69(7):777-785. doi: 10.1016/j.jacc.2016.11.061.	Primary paper from a global prospective registry on atrial fibrillation (GLORIA-AF), where I was co-Chair
6. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GY* , Chen SA*. [*joint senior authors] Should atrial fibrillation patients with 1 additional risk factor of the CHA ₂ DS ₂ -VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol . 2015 Feb 24;65(7):635-42. doi: 10.1016/j.jacc.2014.11.046.	Practice changing paper which shows that even a single non-sex stroke risk factor confers an excess stroke risk, necessitating oral anticoagulation in atrial fibrillation
7. Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY* , Larsen TB* [*joint senior authors] Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ . 2017 Feb 10;356:j510. doi: 10.1136/bmj.j510.	Nationwide data showing the potential risks of under-dosing of direct oral anticoagulation for stroke prevention in atrial fibrillation
8. Guo Y, Lane DA, Wang L, Zhang H, Wang H, Zhang W, Wen J, Xing Y, Wu F, Xia Y, Liu T, Wu F, Liang Z, Liu F, Zhao Y, Li R, Li X, Zhang L, Guo J, Burnside G, Chen Y, Lip GYH ; mAF-App II Trial Investigators. Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation. J Am Coll Cardiol . 2020 Apr 7;75(13):1523-1534. doi: 10.1016/j.jacc.2020.01.052. PMID: 32241367.	Cluster randomised trial comparing ABC pathway versus usual care, showing a significant reduction in the primary outcome of 'stroke, embolism, bleeding and hospitalisation'.
9. Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, Yan L, Xing Y, Shi H, Li S, Liu Y, Liu F, Feng M, Chen Y, Lip GYH ; MAFA II Investigators. Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. J Am Coll Cardiol . 2019 Nov 12;74(19):2365-2375. doi: 10.1016/j.jacc.2019.08.019.	Large population based screening for atrial fibrillation using smartwear, published even before the AppleWatch study, and showing the feasibility and accuracy of such an approach to AF screening.
10. Chu M, Zhang S, Gong J, Yang S, Yang G, Sun X, Wu D, Xia Y, Jiao J, Peng X, Peng Z, Hong L, Wang Z, Li M, Lip GYH* , Chen M*; MIRACLE-AF Investigators. Telemedicine-based integrated management of atrial fibrillation in village clinics: a cluster randomized trial. Nat Med . 2025 Feb 21. doi: 10.1038/s41591-025-03511-2 [*senior authors]	Primary paper of the MIRACLE-AF trial, showing delivery of the ABC pathway by village doctors in rural villages was associated with improved clinical outcomes, compared to usual care

~4488 publications cited on PubMed/Medline, on atrial fibrillation, hypertension, stroke, thrombosis, antithrombotic therapy, etc. **h-index 268; i10-index 1986; 670503 citations on Google Scholar, as on 21 November 2025**

Links: Google scholar profile: <https://scholar.google.co.uk/citations?user=cqY4wxQAAAAJ&hl=en>

Publications on PubMed: <https://pubmed.ncbi.nlm.nih.gov/?term=lip+g&sort=date&size=200>

AD Scientific Index Rankings: <https://www.adscientificindex.com/scientist.php?id=1590656>

Major Research Interests

My research work has delivered crucial impacts in defining the pathophysiology of thrombosis in atrial fibrillation (AF), which is the commonest cardiac rhythm disorder globally; the clinical epidemiology of risk factors; and patient management pathways. This work has led to changes in national and international clinical practice guidelines and improvements in patient care. These have ultimately led to reduced morbidity and mortality for a significant proportion of the population, particularly among the elderly (where AF is more common).